BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCardia (NASDAQ:BCDA), a company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, will host its Q2 2025 earnings conference call on August 11, 2025 at 4:30 PM ET.
The company will provide a corporate update and discuss financial results for the quarter ended June 30, 2025. The call will include management remarks followed by a Q&A session. Participants can join through a dial-in number after registration or via webcast.
Details
News Market Reaction – BCDA
On Aug 6, the day this news came out, BCDA closed 5.52% below the previous close.
Data tracked by StockTitan Argus for the Aug 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to https://dpregister.com/sreg/10201553/ff96e5f036. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZDm6XgM2.
A webcast replay of the call will be available approximately one hour after the end of the call at the above links. A telephonic replay of the call will be available and may be accessed by calling 1-877-344-7529 (domestic), 1-412-317-0088 (international) or 855-669-9658 (Canada) by using access code 7650783.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Marketing / Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.